Scott Wright, MD, Professor of Medicine, Chair of the IRB at the Mayo Clinic. In this video, he speaks about the Phase III ORION-9,10, and 11 Studies. In summary: This is a placebo-controlled, double-blind, randomized Phase III research in patients with ASCVD with increased LDL-C despite the maximum tolerated dose of LDL-C lowering treatments to assess the efficacy, safety, and tolerability of subcutaneous (SC) inclisiran injection (s). The study will be conducted in multiple locations across the United States. - Acute Coronary Syndromes - 767_600c9efaa3c99

Podcast Scott Wright, MD @ScottWrightMD @MayoClinic #ORIONStudies Phase III ORION-9,10, and 11 Studies

Podcast Scott Wright, MD @ScottWrightMD @MayoClinic #ORIONStudies Phase III ORION-9,10, and 11 Studies

1 week
1 Views
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Scott Wright, MD, Professor of Medicine, Chair of the IRB at the Mayo Clinic. In this video, he speaks about the Phase III ORION-9,10, and 11 Studies.

 

In summary:

 

This is a placebo-controlled, double-blind, randomized Phase III research in patients with ASCVD with increased LDL-C despite the maximum tolerated dose of LDL-C lowering treatments to assess the efficacy, safety, and tolerability of subcutaneous (SC) inclisiran injection (s). The study will be conducted in multiple locations across the United States.

Up Next Autoplay